Life expectancy in peritoneal carcinomatosis depends above all on whether the disease can be removed completely with surgery. With systemic treatment alone, published median survival is between 6 and 12 months. When a complete cytoreduction (CC-0) combined with HIPEC is achieved in selected patients, those medians rise to 40-60 months, and in low-grade pseudomyxoma peritonei 10-year survival exceeds 50-70%. The difference between one scenario and the other is not set by the diagnosis, but by the type of primary tumour, the extent measured with the PCI score, the patient's general condition and the experience of the centre assessing the case.
What is the life expectancy in peritoneal carcinomatosis?
There is no single figure. Published median survival ranges from 6-12 months in inoperable disease treated only with systemic chemotherapy, to 40-60 months when a complete cytoreduction with HIPEC is achieved. In patients with residual tumour larger than 2.5 mm after surgery, the median falls to 12-20 months, which shows how much the surgical result shapes the prognosis. By tumour origin, pseudomyxoma peritonei is the most favourable (50-70% survival at 10 years), peritoneal mesothelioma reaches medians of 60-92 months, colorectal origin 30-50% survival at 5 years against less than 5% with chemotherapy alone, ovarian origin 35-55 months and gastric origin 18-24 months in highly selected cases. These figures come from series at specialist centres and from patients who met strict selection criteria, so they cannot be extrapolated to any clinical situation.
It helps to understand what a median is: the point at which half the patients in a study are still alive, not an individual prediction. Half of those patients live longer, and some of them much longer. None of these figures describes what will happen to a specific person, which is why they should always be read together with the assessment of a team that has seen the case.
Which factors determine the prognosis?
Four factors explain most of the variability. The first is the possibility of complete cytoreduction: it is the only prognostic factor that can be acted on directly and the one that carries most weight. The second is the extent of the disease, measured with the PCI score: below 10 the prognosis is favourable, between 10 and 20 intermediate, and above 20 it worsens markedly. The third is the primary tumour, which determines both the biology and the response to chemotherapy. The fourth is the patient's general condition: age, comorbidities and nutritional status determine which treatments can be offered and how well they are tolerated. A fifth, external factor is added to these: the centre's case volume. The relative weight of each one is not fixed: in pseudomyxoma with a high PCI, cytoreduction is still feasible, while in gastric origin a PCI of 15 usually rules out surgery already.
Extensive involvement of the small bowel deserves a separate mention, because it is the finding that most often prevents a complete cytoreduction. General condition, on the other hand, can be improved before surgery: prehabilitation and nutritional optimisation increase the number of patients who can undergo complex surgery.
Does the prognosis change depending on the tumour of origin?
Yes, very markedly. Pseudomyxoma peritonei has the best course, with 10-year survival of 50-70% and results close to cure in the low-grade subtypes. Peritoneal mesothelioma reaches medians of 60-92 months when treated with cytoreductive surgery and HIPEC at expert centres. Colorectal origin sits at 30-50% survival at 5 years in selected patients. Ovarian cancer shows medians of around 35-55 months and tolerates a higher PCI because of its chemosensitivity. Gastric origin is the hardest to control, with medians of 18-24 months even with strict selection. The explanation lies in biology: each primary tumour has a different growth rate, pattern of peritoneal seeding and sensitivity to chemotherapy, and those three variables determine both whether surgery is possible and how long disease control lasts after it. That is why the first thing to establish about any survival figure is which tumour origin it refers to.
This hierarchy has a practical consequence: a figure read for one type of tumour cannot be transferred to another. You can review the detail in the analysis of survival by tumour origin.
How much does cytoreductive surgery with HIPEC improve the prognosis?
In well-selected patients, the difference is of the order of years, not months. Cytoreductive surgery aims to remove all visible disease from the abdomen, and HIPEC (hyperthermic intraperitoneal chemotherapy) acts on the residual microscopic disease that the scalpel cannot reach. Patients who finish the operation with no visible residual tumour (CC-0) reach medians of 40-60 months, against 12-20 months when disease larger than 2.5 mm remains. In carcinomatosis of colorectal origin, 5-year survival rises from less than 5% with systemic chemotherapy alone to 30-50% with the combined approach. The indication for HIPEC must be individualised, because not all tumour origins benefit to the same extent. Outside those settings, adding HIPEC to an incomplete cytoreduction does not improve results and does add morbidity, which is why patient selection matters as much as technique. The best data available relate to pseudomyxoma, mesothelioma and selected cases of colorectal and ovarian origin.
That is why the deciding factor is not only whether the patient is operated on, but who operates. Centres that perform more than 30 cytoreduction with HIPEC procedures a year consistently achieve better CC-0 rates, lower perioperative mortality and better long-term survival. This is the reason why choosing a centre and asking for a second opinion are part of the treatment.
What happens if surgery is not feasible?
When complete cytoreduction is not possible, the prognosis then depends on controlling the disease with systemic treatments and on managing symptoms. Chemotherapy, targeted therapies and immunotherapy still provide control for variable periods, and in selected cases PIPAC (pressurised intraperitoneal aerosol chemotherapy) can be considered as a palliative alternative that reduces ascites and improves tolerance. It is important to point out that "inoperable" is not always a final conclusion: sometimes it means that a particular centre does not perform this type of surgery, or that the assessment was made before giving neoadjuvant chemotherapy that later reduces the tumour burden and reopens the surgical option. Reassessment also has a time window: repeating imaging after two or three cycles of chemotherapy makes it possible to distinguish patients who respond, in whom surgery is considered again, from those in whom progression argues against an aggressive operation. That distinction changes management in a far from negligible number of cases.
Every year we assess cases ruled out at other centres that, after reassessment with up-to-date tests or a diagnostic laparoscopy, turn out to be operable. When they really are not, supportive care and the multidisciplinary approach remain decisive in maintaining quality of life.
Why do two patients with the same diagnosis follow different courses?
Because tumour biology varies between people with the same histological diagnosis. Two carcinomatoses of colorectal origin with a similar PCI can respond in opposite ways to the same chemotherapy depending on the tumour's molecular profile, its growth rate and its pattern of spread. On top of that there are differences in general condition, in the functional reserve needed to tolerate an operation lasting several hours and in the timing of the diagnosis. Survival figures are averages of heterogeneous populations, and applying them to an individual case as if they were a date is a common misreading. Added to this is the effect of the treatment received up to that point: the chemotherapy line used, the time that passed before the peritoneal involvement was diagnosed and whether or not the case was reviewed by a committee with experience in peritoneal surgery. Two clinical histories that are identical on paper rarely are in practice.
The practical consequence is that the prognosis is reviewed throughout the process. A good response to neoadjuvant chemotherapy, a more complete cytoreduction than expected or a limited recurrence suitable for reoperation change the picture. Being followed by a specialist team makes it possible to adjust decisions at each of those points.
Would you like your case assessed? At Quenet Torrent Institute we treat peritoneal carcinomatosis with cytoreductive surgery and HIPEC, and we review cases that other centres have considered inoperable. Request a second opinion.